
Nurses and NPs share how they manage rash, stomatitis, diarrhea, dose holds, cost, and trial eligibility with oral daraxonrasib in pancreatic cancer.
“Previously, this mutation has been undruggable, but this is now changing.”
For this episode of “The Vitals,” we spoke with Kristin Barber, FNP-BC, AOCNP, Huntsman Cancer Institute, about understanding the MAP kinase signaling pathway and some of the ongoing trials targeting these mutations in gastrointestinal oncology.
Barber discussed some of the ongoing phase 1 trials she is participating in and how she hopes the results of these trials could change patient outcomes following targeted treatment.






